Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 145 versus placebo in adults with heterozygous familial hypercholesterolemia
NL-OMON36148Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing AMG 145 with Placebo (2 arms). Primary endpoint: Percent change from baseline in LDL-C at week 12. Started Oct 2011; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON36148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36148.